The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ABBVIE INC. COM 00287Y109 888 10,000 SH   SOLE   10,000 0 0
ACHILLION PHARMACEUTICALS INC COM 00448Q201 9,594 2,136,800 SH   SOLE   2,136,800 0 0
ADVAXIS INC COM NEW 007624208 1,417 339,180 SH   SOLE   339,180 0 0
APRICUS BIOSCIENCES INC COM NEW 03832V307 2,475 1,447,906 SH   SOLE   1,447,906 0 0
BIOGEN INC COM 09062X103 120,193 383,858 SH   SOLE   383,858 0 0
BIOVERATIV INC COM 09075r100 66,486 1,165,000 SH   SOLE   1,165,000 0 0
INNOVIVA INC COM 45781M101 50,841 3,600,705 SH   SOLE   3,600,705 0 0
MEDICINES CO COM 584688105 64,894 1,752,000 SH   SOLE   1,752,000 0 0
NOVELION THERAPEUTICS INC COM NEW 67001K202 7,205 1,025,000 SH   SOLE   1,025,000 0 0